Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2025-01-17 pm EST 		5-day change 1st Jan Change
0.9131 USD +1.68% Intraday chart for Imunon, Inc. +1.47% -3.88%
Dec. 19 IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer CI
Dec. 10 Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 CI

Search
See the results
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Dec. 19
 AQ
IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Dec. 19
 CI
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Dec. 10
 AQ
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001
Dec. 10
 CI
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
Nov. 25
 AQ
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
Nov. 25
 CI
Imunon, Inc., Q3 2024 Earnings Call, Nov 07, 2024
Nov. 07
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
Nov. 07
 AQ
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001
Nov. 07
 CI
IMUNON : Reports Third Quarter 2024 Financial Results and Provides Business Updates Form 8 K
Nov. 07
 PU
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 07
 CI
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
Nov. 07
 AQ
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
24-10-31
 AQ
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
24-10-30
 AQ
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
24-10-30
 CI
IMUNON : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Form 8 K
24-10-07
 PU
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary
24-10-07
 CI
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
24-10-07
 AQ
IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
24-09-10
 AQ
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
24-09-09
 AQ
Imunon Files for Stock Resale by Security Holders
24-08-29
 MT
IMUNON to Host R&D Day on September 18th
24-08-28
 AQ
Imunon, Inc. announced that it has received $10 million in funding
24-08-15
 CI
Imunon, Inc., Q2 2024 Earnings Call, Aug 14, 2024
24-08-14
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
24-08-14
 AQ
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNN Stock
  4. News Imunon, Inc.